Brief: Sigilon Therapeutics Announces Strategic Reprioritization
13/12/2021 22:36
Dec 13 (Reuters) - Sigilon Therapeutics Inc SGTX.O :
* SIGILON THERAPEUTICS ANNOUNCES STRATEGIC REPRIORITIZATION
* SIGILON THERAPEUTICS INC - WORKFORCE REDUCTION OF
APPROXIMATELY
38%
* SIGILON THERAPEUTICS INC - ANTICIPATED CASH RUNWAY
EXTENDED INTO
2024
* SIGILON THERAPEUTICS - DOESN'T EXPECT TO INITIATE DOSING
IN
PHASE 1/2 CLINICAL TRIAL OF SIG-005 FOR MPS-1 UNTIL FURTHER
INVESTIGATION IS COMPLETE
Source text for Eikon: ID:nGNXbGp4W9
Further company coverage: SGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sigilon Therapeutics
See all newsSigilon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Sigilon Therapeutics Inc expected to post a loss of $4.71 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Micron, Greenbrier, Immunome
Sigilon jumps on Eli Lilly's buyout deal to expand diabetes treatments
U.S. STOCKS ON THE MOVE-Sigilon, Netflix, RenovoRx